Blueprint Medicines (NASDAQ:BPMC) Announces Earnings Results
Blueprint Medicines (NASDAQ:BPMC) posted its quarterly earnings data on Thursday. The biotechnology company reported ($2.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.08) by ($0.20), MarketWatch Earnings reports. The business had revenue of $8.34 million during the quarter, compared to analysts’ expectations of $7.56 million. Blueprint Medicines had a negative net margin of 525.44% and a negative return on equity of 71.24%.
BPMC stock opened at $73.18 on Friday. Blueprint Medicines has a 1 year low of $43.29 and a 1 year high of $101.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 7.17 and a quick ratio of 7.14. The firm has a market capitalization of $3.97 billion, a PE ratio of -9.54 and a beta of 1.09. The business has a 50 day simple moving average of $76.68 and a 200-day simple moving average of $67.22.
In related news, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $64.67, for a total value of $1,293,400.00. Following the completion of the sale, the chief executive officer now owns 161,434 shares of the company’s stock, valued at $10,439,936.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Lydon sold 26,007 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $80.45, for a total transaction of $2,092,263.15. Following the sale, the director now owns 48,340 shares of the company’s stock, valued at $3,888,953. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,349 shares of company stock worth $5,001,908. 3.81% of the stock is currently owned by company insiders.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Article: How Investors Can Profit from Options Trading
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.